Axxam and Promega announce agreement to develop smart assays for drug discovery service

This agreement combines the expertise of global biotechnology manufacturer Promega in the creation and production of a large spectrum of luminescence-based tools with the strong background and capabilities of Axxam in the generation of cell-free and cell-based assays and HTS. The strategy aims at offering services for target identification/validation as well for hit discovery based on innovative assays able to smartly monitor important cellular processes like protein degradation, protein-protein and protein-nucleotide interactions, protein secretion, RNA splicing and transcription modulation.

These drug discovery platforms and expertise can be accessed, under a single contractual and project management arrangement, by pharmaceutical and biotech companies, as well as academic translational organizations around the world.